Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is.
Elite FIRST to File: Filed with FDA - 17 August 2023
ask when accord filed oxycontin with fda
Accord filed an abbreviated new drug application (ANDA) for approval to market a generic version of Purdue Pharma’s OxyContin® branded extended release oxycodone hydrochloride tablets.
Do they have OxyContin approved already ??
I looked in Orange Book under Accord no oxycodone
We may not be first with OxyContin:
this was reprinted in 2023 from 2004 originally
May not apply any more or may need re approval ??
https://www.inquirer.com/archive/oxycontin-generic-approval-fda-endo-tevin-20040325.html
Looking for generic OxyContin update
What your target ??
I think Adderall is pushing 10%
Others less. Some of our small drugs with few competitors is higher.
Conservatively I’m using 5% for most.
Vyvance is one to watch due to extreme shortage. If we can get quota and API we could get 10%.
OxyContin could also be Huge !!! especially if we get in quick at first or second .
GLTy hope this gets to you my internet is acting up
Add up the market values:
1. Methotrexate $63.4M
2. Tylenol with Codeine $43M
3. Percocet $500M
4. Norco$477M
5. Methadone 30M
6. Vyvanse$5.10 Billion
7. Dopamine Agonist $12M
8. OxyContin $720M
9. Concerta $1.16 Billion
I smoked my calculator
Elite has the potential to take significant market value of Vyvance and Oxycontin
PULLED TRANSCRIPT FROM LATEST CONFERENCE CALL:
Sales and distribution is what's really leading our increase in revenues. Elite's transition to direct sales with our Elite label has been a great success. The revenue and profit growth demonstrates that success. A testament to our great team, especially Doug Plassche in the operation team, and Kirko Kirkov and his sales organization and the rest of my senior staff. Everybody is doing an excellent job coming together to get us to where we're at.
The highest revenue generating products for Elite label continue to be the mixed Amphetamines, IR (390 Million) , and ER ($1.56 Billion) We see strong market demand for these products. The sales are limited only by how much quota we can get. Managing the quota for these products is very important and our team has done an excellent job managing the quarter. Our other products, Phendimetrazine, Isradipine, Trimipramine have achieved smaller revenues than Amphetamine, but they have strong market shares and they are contributing to their revenues substantially.
In addition, to sales for the Elite label, we also have two licensees, Prasco. Prasco has a non-exclusive license for the Amphetamine ER and sells under the Burel label. This product was launched the first quarter of this year and is doing well. Precision Dose has a license for Naltrexone and Phentermine tablets and capsules and they sell under the Taggy name label and Precision Dose label.
Naltrexone continues to be on the FDA shortage list. Elite has other products that will enhance our pipeline, substantially increase our revenues that will be launched soon.
1. The first product is generic Methotrexate $63.4 Million - DONE . Methotrexate was recently approved by the FDA and will be launched this quarter.
2. The second product is generic APAP with Codeine $45 Million. The brand name is Tylenol and Codeine. APAP with Codeine was approved a few years ago, but we waited until we saw a market need before launching it. We believe the time is now. We expect the launch of APAP with Codeine to be shortly after Methotrexate, six to eight weeks.
3. The third product is Oxy APAP $500 Million, which is Generic Percocet. We expect to launch Oxy APAP six to eight weeks after APAP with codeine.
4. The fourth product is Hydro APAP $477 Million which is the generic for Norco and that will follow Oxy APAP.
5. The fifth product is Methadone $30 Million and we will launch that after Oxy, Hydro APAP. Of the five products that I mentioned, Elite would launch at least three within the next four months.
6. The sixth product to be launched is the central nervous system attention deficit disorder product (GENERIC VYVANSE, pending FDA approval 5.1 Billion. This is the most important of all the products I spoke of. This product will have launch priority over all other products once approved. Now we can only plan for what’s in the queue and what we have. We have everything we need to launch the central nervous system attention deficit disorder medication. Once the FDA gives us approval, we reprioritize everybody else and this will go next.
Elite maintained a strong cash position during our transition to sales. We have supported working capital needs as well as R&D pipeline cost, while maintaining our cash levels. The new product launches will substantially increase our profits and revenues. We will see incremental increases over the next two to three quarters.
Nothing’s going to happen overnight. You launch the first product, you’re going to go through the growing pains that Carter described and then starts to become viable. You launch the second, you go through the same thing. So it’s all coming, and it’s coming quarter-after-quarter.
Regarding the research and development pipeline, Elite has three ANDA filed that are under review by FDA. Generic dopamine agonist ANDA for the treatment of Parkinson’s, and ANDA for the treatment of pain management OxyContin ($720 Million), and the central nervous system stimulus ANDA (Vyvance) $5.1 Billion used for ADHD FDA reviews continue for these products and Elite continues to provide support to any FDA request. Elite will issue a PR upon approval.
Now, two of the three products that I mentioned are needle movers. So let me say a few more words about that. Regarding the CMS application, the FDA asked us to make a couple of minor adjustment. Tighten the spec, move this over here and there, nothing of relevance. But the FDA did request an extra month to review the DMF for the API supplier.
So our PDUFA date is November. That was very nice of FDA to do that, because they found that our application itself doesn’t have any issues or all the issues we had, we resolved them over the past year. They had a question to the DMF supplier, and instead of saying, take this back and call us back in a year or in six months or whatever, they actually said, we need another month to resolve some issues, which is really very promising. And we will update you in November once we hear – if we hear from FDA and what their verdict is.
Regarding second needle mover the pain management and generic OxyContin ($720 Million), it’s one of the common outcomes of a paragraph IV ANDA filing is a lawsuit by the brand company, and we have updated you on that. We’re going through that right now. We agreed with Purdue to renew the litigation hold for six more months. It does not make any sense for us to get engaged with lawsuits with Purdue at this time, because they have enough people suing them and trying to invalidate their patents. So we stepped back and agreed that we will take six months where we don't go through discovery, we don't have to spend the money, they don't have to come after us till we see what's happening in the landscape. If a judge says patents are invalidated, will move in. If they say they are not, we're in the same boat as everybody else.
Elite has other products in the formulation development stage that have not reached a reportable milestone yet. Elite continues to make R&D a priority……... Regarding the facility and infrastructure, as you know, to keep up with our growth, we needed additional space. So we have taken on an additional 34,000 square feet to support expanding packaging, inventory and warehouse holding.
We closed the deal and took possession of the facility last January. The permits were obtained for construction because it's a part, 34,000 square feet is a part of a building that's about 85,000 square feet. We have to seal it and close it to make it into pharmaceutical. We build the IT infrastructure, the servers, the cameras, ADT security, all of them are ready. A state of the art packaging line that's already been qualified and ready. Department of Health got approval, then the CDS approval. The two remaining things were DEA and FDA.
The vault and all the security already. We invited the FDA last week. They showed up Monday, and I am happy to report that the inspection went very well. In my opinion, the DEA takes, usually regulatory agencies in general take 45 days to write the report. I expect approval by the DEA within that time. Before we meet in November for sure, but I believe within 45 days we'll receive approval from the DEA.
The next step is FDA – next and final step is the FDA approval. To get the FDA approval, we have to manufacture or package lots at the facility, put them on three months stability, and then file with the FDA for them to come in and inspect and give us approval. The lots are being packaged right now. The lines are qualified, including serialization, all of that. They are being made right now placed on stability by next week or the week after. Three months should be about November, I expect that we’ll file towards the end of November, and then it’s a matter of when the FDA can approve it and we’ll update you on that once we know. At the end of the day, once this facility is approved, we should have and be covered from the expansion standpoint for at least five years for manufacturing and longer than that for packaging.
In summary, Elite has shown strong growth this quarter. We are executing the company’s strategies for commercial, sales and distribution and research and development. Elite has the best commercial product line it has ever had an excellent pipeline of approved and soon-to-be approved products, and the best financial position in the company’s history.
This puts Elite in a strong position for an M&A or a move to NASDAQ when the time is right..
Never won a spelling bee ?
HAMMER TIME !!!
HAMMER TIME !!!!!!
I just picked up a few more shares. Came into some free money.
HAMMER TIME !!!
Upcoming ELTP Catalysts:
UPDATE :
Going right down the line !!!!
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__26. Generate revenues over $20 million/quarter
__27. Final Approval of New Manufacturing Facility/Expansion
__28. Double output of manufacturing and packaging facilities
__29. Launch approved generic Tylenol with Codeine $45 Million
__30. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__31. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__32. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
__33. Generic Vyvanse Approval and Launch
__34. Generic Concerta- FDA submission $1.2 BILLION
__35. $100 million in yearly revenue
__36. Generic OxyContin Tentative Approval $720 Million
__37. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__38.Launch generic OxyContin $720 Million
__39. Resume R&D on SequestOx Abuse Deterrent Oxycodone
__40. European distribution - Dexcel partnership approval by Israeli Health
__41. $200 million in yearly revenue
__42. Patented Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__43. Undisclosed Mikah ANDA(s)
__44. Undisclosed ANDAs/NDAs
__45. Generic Concerta Approval and Launch
__46. DollarLand PPS
__47. Big Pharma bid
__48. UpList to the NASDAQ Exchange
__49. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
Bullish
Maybe buy shares first, LOL
Not 2 cents any more.
Isee you on the bid.
I agree but could be as early as November.
Im taking the time to load before we get to a Dollar
GLTY
$$$$$$$$$$$$$$$$$$$$$ ELTP
I think he thinks Elite is going to $78
My Pharmacist says the patients are loving Elites meds. Friends say they cant tell difference to name brand except price.
Good luck getting cheaper shares. Your game will be over with Vyvance approval in Oct or Nov
$5.1 Billion market
Your up against a combined $10 Billion market of ANDAs
A conservative 5% gets us $500 million a year
Locked and Loaded
ELTP
Nasrat has a HammerLock on OxyContin.
$720 million market
ELTP
Wait 6 months for $5.00
Elite Pharmaceuticals' profitability score of 79/100 indicates strong performance relative to many of its industry peers. Here's how this compares to other pharmaceutical companies:
Profitability Score Context
A profitability score of 79/100 suggests that Elite Pharmaceuticals is more profitable than approximately 79% of companies in its industry. This places it in the top quartile for profitability among pharmaceutical firms.
Key Profitability Metrics
To understand how Elite Pharmaceuticals achieves this high score, let's examine some key metrics:
Margins
Gross Profit Margin: 46.6%
Operating Profit Margin: 19.1%
Net Profit Margin: 35.5%
These margins are generally considered strong for the pharmaceutical industry, indicating efficient cost management and pricing power.
PULLED TRANSCRIPT FROM LATEST CONFERENCE CALL:
Sales and distribution is what's really leading our increase in revenues. Elite's transition to direct sales with our Elite label has been a great success. The revenue and profit growth demonstrates that success. A testament to our great team, especially Doug Plassche in the operation team, and Kirko Kirkov and his sales organization and the rest of my senior staff. Everybody is doing an excellent job coming together to get us to where we're at.
The highest revenue generating products for Elite label continue to be the mixed Amphetamines, IR (390 Million) , and ER ($1.56 Billion) We see strong market demand for these products. The sales are limited only by how much quota we can get. Managing the quota for these products is very important and our team has done an excellent job managing the quarter. Our other products, Phendimetrazine, Isradipine, Trimipramine have achieved smaller revenues than Amphetamine, but they have strong market shares and they are contributing to their revenues substantially.
In addition, to sales for the Elite label, we also have two licensees, Prasco. Prasco has a non-exclusive license for the Amphetamine ER and sells under the Burel label. This product was launched the first quarter of this year and is doing well. Precision Dose has a license for Naltrexone and Phentermine tablets and capsules and they sell under the Taggy name label and Precision Dose label.
Naltrexone continues to be on the FDA shortage list. Elite has other products that will enhance our pipeline, substantially increase our revenues that will be launched soon.
1. The first product is generic Methotrexate $63.4 Million - DONE . Methotrexate was recently approved by the FDA and will be launched this quarter.
2. The second product is generic APAP with Codeine $45 Million. The brand name is Tylenol and Codeine. APAP with Codeine was approved a few years ago, but we waited until we saw a market need before launching it. We believe the time is now. We expect the launch of APAP with Codeine to be shortly after Methotrexate, six to eight weeks.
3. The third product is Oxy APAP $500 Million, which is Generic Percocet. We expect to launch Oxy APAP six to eight weeks after APAP with codeine.
4. The fourth product is Hydro APAP $477 Million which is the generic for Norco and that will follow Oxy APAP.
5. The fifth product is Methadone $30 Million and we will launch that after Oxy, Hydro APAP. Of the five products that I mentioned, Elite would launch at least three within the next four months.
6. The sixth product to be launched is the central nervous system attention deficit disorder product (GENERIC VYVANSE, pending FDA approval 5.1 Billion. This is the most important of all the products I spoke of. This product will have launch priority over all other products once approved. Now we can only plan for what’s in the queue and what we have. We have everything we need to launch the central nervous system attention deficit disorder medication. Once the FDA gives us approval, we reprioritize everybody else and this will go next.
Elite maintained a strong cash position during our transition to sales. We have supported working capital needs as well as R&D pipeline cost, while maintaining our cash levels. The new product launches will substantially increase our profits and revenues. We will see incremental increases over the next two to three quarters.
Nothing’s going to happen overnight. You launch the first product, you’re going to go through the growing pains that Carter described and then starts to become viable. You launch the second, you go through the same thing. So it’s all coming, and it’s coming quarter-after-quarter.
Regarding the research and development pipeline, Elite has three ANDA filed that are under review by FDA. Generic dopamine agonist ANDA for the treatment of Parkinson’s, and ANDA for the treatment of pain management OxyContin ($720 Million), and the central nervous system stimulus ANDA (Vyvance) $5.1 Billion used for ADHD FDA reviews continue for these products and Elite continues to provide support to any FDA request. Elite will issue a PR upon approval.
Now, two of the three products that I mentioned are needle movers. So let me say a few more words about that. Regarding the CMS application, the FDA asked us to make a couple of minor adjustment. Tighten the spec, move this over here and there, nothing of relevance. But the FDA did request an extra month to review the DMF for the API supplier.
So our PDUFA date is November. That was very nice of FDA to do that, because they found that our application itself doesn’t have any issues or all the issues we had, we resolved them over the past year. They had a question to the DMF supplier, and instead of saying, take this back and call us back in a year or in six months or whatever, they actually said, we need another month to resolve some issues, which is really very promising. And we will update you in November once we hear – if we hear from FDA and what their verdict is.
Regarding second needle mover the pain management and generic OxyContin ($720 Million), it’s one of the common outcomes of a paragraph IV ANDA filing is a lawsuit by the brand company, and we have updated you on that. We’re going through that right now. We agreed with Purdue to renew the litigation hold for six more months. It does not make any sense for us to get engaged with lawsuits with Purdue at this time, because they have enough people suing them and trying to invalidate their patents. So we stepped back and agreed that we will take six months where we don't go through discovery, we don't have to spend the money, they don't have to come after us till we see what's happening in the landscape. If a judge says patents are invalidated, will move in. If they say they are not, we're in the same boat as everybody else.
Elite has other products in the formulation development stage that have not reached a reportable milestone yet. Elite continues to make R&D a priority……... Regarding the facility and infrastructure, as you know, to keep up with our growth, we needed additional space. So we have taken on an additional 34,000 square feet to support expanding packaging, inventory and warehouse holding.
We closed the deal and took possession of the facility last January. The permits were obtained for construction because it's a part, 34,000 square feet is a part of a building that's about 85,000 square feet. We have to seal it and close it to make it into pharmaceutical. We build the IT infrastructure, the servers, the cameras, ADT security, all of them are ready. A state of the art packaging line that's already been qualified and ready. Department of Health got approval, then the CDS approval. The two remaining things were DEA and FDA.
The vault and all the security already. We invited the FDA last week. They showed up Monday, and I am happy to report that the inspection went very well. In my opinion, the DEA takes, usually regulatory agencies in general take 45 days to write the report. I expect approval by the DEA within that time. Before we meet in November for sure, but I believe within 45 days we'll receive approval from the DEA.
The next step is FDA – next and final step is the FDA approval. To get the FDA approval, we have to manufacture or package lots at the facility, put them on three months stability, and then file with the FDA for them to come in and inspect and give us approval. The lots are being packaged right now. The lines are qualified, including serialization, all of that. They are being made right now placed on stability by next week or the week after. Three months should be about November, I expect that we’ll file towards the end of November, and then it’s a matter of when the FDA can approve it and we’ll update you on that once we know. At the end of the day, once this facility is approved, we should have and be covered from the expansion standpoint for at least five years for manufacturing and longer than that for packaging.
In summary, Elite has shown strong growth this quarter. We are executing the company’s strategies for commercial, sales and distribution and research and development. Elite has the best commercial product line it has ever had an excellent pipeline of approved and soon-to-be approved products, and the best financial position in the company’s history.
This puts Elite in a strong position for an M&A or a move to NASDAQ when the time is right..
Upcoming ELTP Catalysts:
UPDATE :
Going right down the line !!!!
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__26. Generate revenues over $20 million/quarter
__27. Final Approval of New Manufacturing Facility/Expansion
__28. Double output of manufacturing and packaging facilities
__29. Launch approved generic Tylenol with Codeine $45 Million
__30. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__31. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__32. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
__33. Generic Vyvanse Approval and Launch
__34. Generic Concerta- FDA submission $1.2 BILLION
__35. $100 million in yearly revenue
__36. Generic OxyContin Tentative Approval $720 Million
__37. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__38.Launch generic OxyContin $720 Million
__39. Resume R&D on SequestOx Abuse Deterrent Oxycodone
__40. European distribution - Dexcel partnership approval by Israeli Health
__41. $200 million in yearly revenue
__42. Patented Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__43. Undisclosed Mikah ANDA(s)
__44. Undisclosed ANDAs/NDAs
__45. Generic Concerta Approval and Launch
__46. DollarLand PPS
__47. Big Pharma bid
__48. UpList to the NASDAQ Exchange
__49. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
ELTP momentum to continue:
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__26. Generate revenues over $20 million/quarter
__27. Final Approval of New Manufacturing Facility/Expansion
__28. Double output of manufacturing and packaging facilities
__29. Launch approved generic Tylenol with Codeine $45 Million
__30. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__31. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__32. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
__33. Generic Vyvanse Approval and Launch
__34. Generic Concerta- FDA submission $1.2 BILLION
__35. $100 million in yearly revenue
__36. Generic OxyContin Tentative Approval $720 Million
__37. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__38.Launch generic OxyContin $720 Million
__39. Resume R&D on SequestOx Abuse Deterrent Oxycodone
__40. European distribution - Dexcel partnership approval by Israeli Health
__41. $200 million in yearly revenue
__42. Patented Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__43. Undisclosed Mikah ANDA(s)
__44. Undisclosed ANDAs/NDAs
__45. Generic Concerta Approval and Launch
__46. DollarLand PPS
__47. Big Pharma bid
__48. UpList to the NASDAQ Exchange
__49. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
Bullish
Thanks for the heads up. Richme gonna be peed.
SeeQuestOx maybe back on the table since the opioid scare is over ??
Nasrat is not going to let it out of the bag for competitive reasons unless we take on a partner then it will be harder to hide.
We wont know until there is an approval.
You were well on your way to MillionDollarLand.
Sorry for your future losses.
Twice in a week $$$$$$$$$$$$$$
Multi Millionaire run is back on !!!
ELTP
They stole a lot of shares using stop losses.